CoreWeave’s stock is polarizing Wall Street. These are the post-earnings debates.
1. CoreWeave's Q2 revenue grew 200%, but losses exceeded expectations. 2. Stock down 20%, trading triple its IPO price of $40. 3. Analysts have differing views on growth potential and financing. 4. Capacity constraints and high debt are significant concerns. 5. Pending acquisition of Core Scientific may ease supply issues.